EU Policies & Directives
-
Social Health Protection
Despite considerable attention over many decades, striking inequalities among and within countries still exist. Several social factors that can influence health can be found in the image below. The Social…
Lire la suite » -
Orphan Drugs
The Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) is responsible for receiving, approving, and/or rejecting orphan drugs’ designation applications. Markets’ access to Orphan Drugs varies between…
Lire la suite » -
Rare Diseases
In EU countries, any disease affecting fewer than 5 people in 10 000 is considered rare. This number may seem small but it translates into approximately 246.000 people throughout the…
Lire la suite » -
Cross-Border Healthcare
The Directive 2011/24/EU, clarifies that EU patients seeking healthcare outside their country may do so as long as the type of treatment would have been normally provided at home. Payment…
Lire la suite » -
Clinical Trials
Why Participate in a Clinical Trial? There are many reasons why people choose to join a clinical trial. Some join a trial because the treatments they have tried for their health…
Lire la suite » -
Pharmacovigilance
Phamacovigilance is defined as the activities that deal with the detection, assessment, understanding and prevention of adverse effects of medicinal products in consumers, simultaneously undertaking the monitoring of counterfeit products…
Lire la suite » -
Patient Safety
Every year, millions of patients suffer injuries or die because of unsafe and poor-quality health care. Many medical practices and risks associated with health care are emerging as major challenges…
Lire la suite » -
Blood Safety & Availability
Blood Availability Great variability exists regarding availability of blood and blood donation practices among countries, influenced by socioeconomical factors. In high-income countries, blood collection tends to be a well-established practice…
Lire la suite »